Developer docs
API playgroundTry for free, no card

Search company profiles

ObvioHealth

Full company profile

uuid0000swt

Namestring
ObvioHealth
Legal namestring
Obvio Health USA, Inc.
Websiteurl
obviohealth.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

ObvioHealth is a privately held digital clinical trials company founded in 2017 and headquartered in New York, with a Singapore parent entity (ObvioHealth PTE. LTD.) that functions as the holding structure. The company sells ObvioGo, a unified no-code platform that consolidates the decentralized clinical trial (DCT) software stack — eConsent, ePRO/eCOA, participant engagement, virtual visits, logistics and device management, safety monitoring, recruitment, and central rating — into a single environment, replacing what it states is typically 4–6 separate vendor products. The platform was developed operationally over approximately eight years while running more than 60 real trials before being offered as a licensable product, and is delivered via direct enterprise sales to pharma/biotech sponsors, CROs, medical device and digital therapeutics companies, and consumer health brands, alongside channel partnerships (notably Novotech and sister company SPRIM PRO) and API-first integration with dominant EDC systems including Oracle Clinical One, Medidata, and Veeva.

The business model is enterprise SaaS-style subscription and multi-trial licensing with quote-based pricing; the platform is offered as either an enterprise subscription or a multi-trial license to CROs that deploy ObvioGo as a standardized participant-facing digital layer across their programs. Studies reportedly deploy in approximately 4 weeks (versus 12–16+ weeks for legacy stacks), with disclosed portfolio-level metrics of 91% ePRO compliance, 89% participant retention, 50k+ consented participants, and operations across 40 countries and 6 continents. Revenue is not publicly disclosed; cumulative disclosed equity funding through 2022 totals approximately $61.85M, with an additional undisclosed round in October 2025. Compliance posture spans ISO 27001, HIPAA, GDPR, CCPA, SOC 2 Type 2, and EU-U.S. Data Privacy Framework certification.

Customer evidence spans large pharma (Pfizer, Janssen, Abbott, RedHill Pharma), consumer health multinationals (Haleon, Danone, DSM, FrieslandCampina, Mizkan), medical device and digital therapeutics (Renovia), and CRO channels (Novotech, SPRIM PRO). Named customer engagements include a fully virtual urogynecology trial with 350 patients enrolled in 14 weeks, treatment-resistant depression studies across Australia and New Zealand, and vaccine development with Vaxxas. Distribution is direct enterprise plus CRO-led channel; there is no public or partner-facing API, developer portal, or SDK beyond EDC integrations.

Short descriptiontext

ObvioHealth sells ObvioGo, a unified no-code decentralized clinical trial platform that consolidates eConsent, ePRO/eCOA, virtual visits, and device integration into a single system for pharma, biotech, CROs, medical device, and consumer health sponsors globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
decentralized clinical trials, digital clinical trial platform, electronic patient reported outcomes, clinical trial eConsent software, hybrid clinical trial technology
Industry1 code
PRIMARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SIC code1 code
  • Services-Prepackaged Software7372
Product category
Decentralized Clinical Trial Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Platform Licensing
TypeSubscription Recurring
Description

Multi-trial licensing of ObvioGo platform to CROs and sponsors. The platform is licensed across multiple clinical trials as a standardized participant-facing digital layer, enabling reuse of standardized digital workflows across programs.

biospace.com
2Enterprise Platform Subscription
TypeSubscription Recurring
Description

Enterprise-level platform access with modules for eConsent, ePRO/eCOA, remote and hybrid assessments bundled in a unified system. Studies deploy in approximately 4 weeks on average.

obviohealth.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1ObvioGo
Description

Enterprise platform combining eConsent, ePRO/eCOA, and remote and hybrid assessments in a single system for decentralized clinical trials.

obviohealth.com
+1 more record
Core offering1 text field

ObvioHealth provides ObvioGo, an enterprise digital platform for decentralized and hybrid clinical trials that consolidates ePRO, eCOA, eConsent, participant engagement, virtual visits, and device integration into a single no-code environment. The company also operates a COACH clinical oversight team that provides in-app support and monitoring for trial participants. The platform is licensed to pharmaceutical sponsors, biotech firms, CROs, and medical device companies to design, run, and manage remote and hybrid studies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 91% ePRO compliance across portfolio
+6 more records
Product overview1 text field

ObvioHealth offers ObvioGo, an enterprise platform for decentralized and hybrid clinical trials that consolidates what typically requires 4-6 separate vendors—ePRO, eConsent, participant engagement, safety monitoring, device integration—into a single no-code environment. The platform comprises multiple integrated modules including Study Designer (no-code protocol development), Study Manager (analytics and dashboards), and the ObvioGo Mobile App (participant-facing interface), alongside functional modules for eConsent and Enrollment, ePRO + eCOA, Data Capture and Monitoring, Virtual Visits and Support, Recruitment and Prescreening, Logistics and Device Management, and Regulatory and Security. The platform is API-first, enabling direct integration with Oracle Clinical One, Medidata, and Veeva. ObvioHealth also provides the COACH Team (Clinical Oversight and Coordination Hub), a virtual site clinical support service. Studies deploy in approximately 4 weeks on average, with 91% ePRO compliance and 89% participant retention reported across their portfolio.

Product and service5 records
1ObvioGo Platform
CategoryDecentralized Clinical Trial Platform
Description

Enterprise platform combining eConsent, ePRO/eCOA, remote and hybrid assessments, virtual visits, and data capture into a unified system for decentralized and hybrid clinical trials. Targets pharmaceutical sponsors, biotechs, CROs, and medical device companies.

2ObvioGo Mobile App
CategoryMobile Participant Application
Description

Mobile application enabling remote trial participation with eConsent, ePRO/eCOA, image and audio capture, virtual visits, and real-time engagement for clinical trial participants.

3ObvioGo Study Designer
CategoryProtocol Development Tool
Description

No-code, drag-and-drop interface within ObvioGo for building trials from the ground up, simplifying protocol development and adaptation.

4ObvioGo Study Manager
CategoryTrial Analytics Dashboard
Description

Sponsor and investigator-facing tool providing real-time dashboards, data visualization, and analytics capabilities for trial monitoring and outcomes.

5COACH Team (Clinical Oversight and Coordination Hub)
CategoryClinical Trial Support Service
Description

Virtual site clinical team that monitors data submission and patient engagement throughout studies, provides live chat support, ensures streamlined processes, and maintains participant safety.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-24
Description

ObvioHealth announced a strategic multi-trial licensing agreement with Novotech, under which Novotech licenses the ObvioGo platform across multiple clinical trials as a standardized participant-facing digital layer. The agreement enables Novotech teams to reuse standardized digital workflows across programs and reinforces ObvioHealth's role as an enterprise technology partner supporting scalable, sponsor-ready development models.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-10
Description

ObvioGo is now directly integrated with Oracle Clinical One Data Collection, enabling sponsors and CROs to deploy participant-facing trial technologies through a unified clinical trial system. The integration combines ObvioGo's ePRO, eConsent, and eCOA capabilities with Oracle's platform, allowing organizations to limit reliance on multiple third-party solutions while maintaining consistency and scalability across global studies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-28
Description

ObvioHealth and Vaxxas entered a three-year partnership to support clinical trials with Vaxxas' needle-free HD-MAP vaccine technology. The collaboration includes using ObvioGo digital trial platform to facilitate vaccine development and testing, with focus on extending access via decentralized trial capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-15
Description

SPRIM PRO and ObvioHealth, sister companies within the SPRIM Group, expanded their collaboration to offer a fully integrated clinical trial solution combining scientific expertise with digital capabilities. The partnership pairs SPRIM PRO's 24 years of clinical experience across 300+ trials with ObvioHealth's ObvioGo platform for decentralized and hybrid trials. The unified offering helps trial sponsors accelerate study startup, improve participant engagement, and deliver regulatory-ready data.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
TypeDirect peer
Description

THREAD provides a decentralized clinical trial platform supporting eCOA, eConsent, virtual visits, and device integrations. Directly comparable as a DCT technology competitor with similar modular offerings to ObvioGo.

3Oracle Health Sciences (Clinical One)
TypeDirect peer
Description

Oracle's Clinical One platform is a unified clinical trial system providing EDC, RTSM, and eCOA. Comparable to ObvioHealth as both a direct competitor in DCT and a partner via the Clinical One Data Collection integration announced in 2026.

TypeDirect peer
Description

Medable is a leading decentralized clinical trial platform offering eCOA, eConsent, telehealth, and remote monitoring. Directly comparable as a venture-backed DCT software competitor targeting the same pharma/biotech/medical device sponsor base.

TypeEmerging player
Description

Curebase is an emerging DCT platform combining software with virtual site services for decentralized and hybrid trials. Comparable as a younger competitor in the same decentralized trial software + services category ObvioHealth occupies.

TypeDirect peer
Description

Science 37 pioneered the decentralized clinical trial operating model with its patient-facing Metasite technology. Comparable to ObvioHealth as a DCT platform competitor serving large pharma sponsors with remote trial enablement.

TypeEmerging player
Description

Castor offers an eClinical platform with EDC, ePRO, and eConsent capabilities focused on flexibility and integration. Comparable as an emerging modular DCT/clinical trial platform competitor, though more research-grade than large-pharma focused.

TypeBroad incumbent
Description

IQVIA is the world's largest CRO and a strategic investor in ObvioHealth. Comparable as a broad incumbent offering DCT capabilities within its full-service CRO portfolio, and as a channel that can route trials to or away from ObvioGo.

TypeDirect peer
Description

Medidata (Dassault Systèmes) is the dominant eClinical platform with Rave EDC and Patient Cloud ePRO/eConsent. Directly comparable as it offers the same core modules (eCOA, eConsent, remote data capture) that ObvioGo targets, and is the incumbent ObvioHealth explicitly positions against.

TypeDirect peer
Description

Veeva's Vault Clinical platform offers EDC, ePRO, and clinical operations suites widely used in pharma trials. Comparable to ObvioHealth as a Veeva EDC integration partner and as a competing clinical data management platform for enterprise sponsors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers19 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ObvioHealth

Decentralized Clinical Trial Softwareobviohealth.com

ObvioHealth sells ObvioGo, a unified no-code decentralized clinical trial platform that consolidates eConsent, ePRO/eCOA, virtual visits, and device integration into a single system for pharma, biotech, CROs, medical device, and consumer health sponsors globally.

What ObvioHealth does

ObvioHealth is a privately held digital clinical trials company founded in 2017 and headquartered in New York, with a Singapore parent entity (ObvioHealth PTE. LTD.) that functions as the holding structure. The company sells ObvioGo, a unified no-code platform that consolidates the decentralized clinical trial (DCT) software stack — eConsent, ePRO/eCOA, participant engagement, virtual visits, logistics and device management, safety monitoring, recruitment, and central rating — into a single environment, replacing what it states is typically 4–6 separate vendor products. The platform was developed operationally over approximately eight years while running more than 60 real trials before being offered as a licensable product, and is delivered via direct enterprise sales to pharma/biotech sponsors, CROs, medical device and digital therapeutics companies, and consumer health brands, alongside channel partnerships (notably Novotech and sister company SPRIM PRO) and API-first integration with dominant EDC systems including Oracle Clinical One, Medidata, and Veeva.

The business model is enterprise SaaS-style subscription and multi-trial licensing with quote-based pricing; the platform is offered as either an enterprise subscription or a multi-trial license to CROs that deploy ObvioGo as a standardized participant-facing digital layer across their programs. Studies reportedly deploy in approximately 4 weeks (versus 12–16+ weeks for legacy stacks), with disclosed portfolio-level metrics of 91% ePRO compliance, 89% participant retention, 50k+ consented participants, and operations across 40 countries and 6 continents. Revenue is not publicly disclosed; cumulative disclosed equity funding through 2022 totals approximately $61.85M, with an additional undisclosed round in October 2025. Compliance posture spans ISO 27001, HIPAA, GDPR, CCPA, SOC 2 Type 2, and EU-U.S. Data Privacy Framework certification.

Customer evidence spans large pharma (Pfizer, Janssen, Abbott, RedHill Pharma), consumer health multinationals (Haleon, Danone, DSM, FrieslandCampina, Mizkan), medical device and digital therapeutics (Renovia), and CRO channels (Novotech, SPRIM PRO). Named customer engagements include a fully virtual urogynecology trial with 350 patients enrolled in 14 weeks, treatment-resistant depression studies across Australia and New Zealand, and vaccine development with Vaxxas. Distribution is direct enterprise plus CRO-led channel; there is no public or partner-facing API, developer portal, or SDK beyond EDC integrations.

ObvioHealth firmographics

Firmographics
Name
ObvioHealth
Legal name
Obvio Health USA, Inc.
Website
https://obviohealth.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
ObvioHealth sells ObvioGo, a unified no-code decentralized clinical trial platform that consolidates eConsent, ePRO/eCOA, virtual visits, and device integration into a single system for pharma, biotech, CROs, medical device, and consumer health sponsors globally.
Ownership category
akta.pro rank

ObvioHealth industry classification

Industry
Product category
Decentralized Clinical Trial Software
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

Keywords

  • Decentralized clinical trials
  • Digital clinical trial platform
  • Electronic patient reported outcomes
  • Clinical trial eConsent software
  • Hybrid clinical trial technology

Where ObvioHealth is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices3 records

Markets served

ObvioHealth business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Platform Licensing: Multi-trial licensing of ObvioGo platform to CROs and sponsors. The platform is licensed across multiple clinical trials as a standardized participant-facing digital layer, enabling reuse of standardized digital workflows across programs.
  2. Enterprise Platform Subscription: Enterprise-level platform access with modules for eConsent, ePRO/eCOA, remote and hybrid assessments bundled in a unified system. Studies deploy in approximately 4 weeks on average.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

ObvioHealth product offering

Product offering

Core offering

ObvioHealth provides ObvioGo, an enterprise digital platform for decentralized and hybrid clinical trials that consolidates ePRO, eCOA, eConsent, participant engagement, virtual visits, and device integration into a single no-code environment. The company also operates a COACH clinical oversight team that provides in-app support and monitoring for trial participants. The platform is licensed to pharmaceutical sponsors, biotech firms, CROs, and medical device companies to design, run, and manage remote and hybrid studies.

Product overview

ObvioHealth offers ObvioGo, an enterprise platform for decentralized and hybrid clinical trials that consolidates what typically requires 4-6 separate vendors—ePRO, eConsent, participant engagement, safety monitoring, device integration—into a single no-code environment. The platform comprises multiple integrated modules including Study Designer (no-code protocol development), Study Manager (analytics and dashboards), and the ObvioGo Mobile App (participant-facing interface), alongside functional modules for eConsent and Enrollment, ePRO + eCOA, Data Capture and Monitoring, Virtual Visits and Support, Recruitment and Prescreening, Logistics and Device Management, and Regulatory and Security. The platform is API-first, enabling direct integration with Oracle Clinical One, Medidata, and Veeva. ObvioHealth also provides the COACH Team (Clinical Oversight and Coordination Hub), a virtual site clinical support service. Studies deploy in approximately 4 weeks on average, with 91% ePRO compliance and 89% participant retention reported across their portfolio.

Differentiator

Problem solved

Functional benefit

Brands

  • ObvioGo: Enterprise platform combining eConsent, ePRO/eCOA, and remote and hybrid assessments in a single system for decentralized clinical trials.
  • COACH (Clinical Oversight and Coordination Hub)

Products and services

  • ObvioGo Platform Enterprise platform combining eConsent, ePRO/eCOA, remote and hybrid assessments, virtual visits, and data capture into a unified system for decentralized and hybrid clinical trials. Targets pharmaceutical sponsors, biotechs, CROs, and medical device companies.
  • ObvioGo Mobile App Mobile application enabling remote trial participation with eConsent, ePRO/eCOA, image and audio capture, virtual visits, and real-time engagement for clinical trial participants.
  • ObvioGo Study Designer No-code, drag-and-drop interface within ObvioGo for building trials from the ground up, simplifying protocol development and adaptation.
  • ObvioGo Study Manager Sponsor and investigator-facing tool providing real-time dashboards, data visualization, and analytics capabilities for trial monitoring and outcomes.
  • COACH Team (Clinical Oversight and Coordination Hub) Virtual site clinical team that monitors data submission and patient engagement throughout studies, provides live chat support, ensures streamlined processes, and maintains participant safety.

Quantifiable outcome

  • 91% ePRO compliance across portfolio
  • +6 more outcomes

Companies that use ObvioHealth

Customer profile

Named customers19 records

Segments4 records

Ideal customer profiles4 records

ObvioHealth technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability4 records

Feature9 records

ObvioHealth partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • NovotechcoreChannel Partner/ Reseller/ Distributor · 24 February 2026ObvioHealth announced a strategic multi-trial licensing agreement with Novotech, under which Novotech licenses the ObvioGo platform across multiple clinical trials as a standardized participant-facing digital layer. The agreement enables Novotech teams to reuse standardized digital workflows across programs and reinforces ObvioHealth's role as an enterprise technology partner supporting scalable, sponsor-ready development models.
  • Oracle Life SciencescoreTechnology or Integration · 10 February 2026ObvioGo is now directly integrated with Oracle Clinical One Data Collection, enabling sponsors and CROs to deploy participant-facing trial technologies through a unified clinical trial system. The integration combines ObvioGo's ePRO, eConsent, and eCOA capabilities with Oracle's platform, allowing organizations to limit reliance on multiple third-party solutions while maintaining consistency and scalability across global studies.
  • VaxxascoreStrategic or Co-development Partner · 28 October 2025ObvioHealth and Vaxxas entered a three-year partnership to support clinical trials with Vaxxas' needle-free HD-MAP vaccine technology. The collaboration includes using ObvioGo digital trial platform to facilitate vaccine development and testing, with focus on extending access via decentralized trial capabilities.
  • SPRIM PROcoreStrategic or Co-development Partner · 15 July 2025SPRIM PRO and ObvioHealth, sister companies within the SPRIM Group, expanded their collaboration to offer a fully integrated clinical trial solution combining scientific expertise with digital capabilities. The partnership pairs SPRIM PRO's 24 years of clinical experience across 300+ trials with ObvioHealth's ObvioGo platform for decentralized and hybrid trials. The unified offering helps trial sponsors accelerate study startup, improve participant engagement, and deliver regulatory-ready data.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

ObvioHealth competitors and assessment

Company assessment

Broad incumbents

  • ICON plc:
  • IQVIA: IQVIA is the world's largest CRO and a strategic investor in ObvioHealth. Comparable as a broad incumbent offering DCT capabilities within its full-service CRO portfolio, and as a channel that can route trials to or away from ObvioGo.

Direct peers

  • THREAD Research: THREAD provides a decentralized clinical trial platform supporting eCOA, eConsent, virtual visits, and device integrations. Directly comparable as a DCT technology competitor with similar modular offerings to ObvioGo.
  • Oracle Health Sciences (Clinical One): Oracle's Clinical One platform is a unified clinical trial system providing EDC, RTSM, and eCOA. Comparable to ObvioHealth as both a direct competitor in DCT and a partner via the Clinical One Data Collection integration announced in 2026.
  • Medable: Medable is a leading decentralized clinical trial platform offering eCOA, eConsent, telehealth, and remote monitoring. Directly comparable as a venture-backed DCT software competitor targeting the same pharma/biotech/medical device sponsor base.
  • Science 37: Science 37 pioneered the decentralized clinical trial operating model with its patient-facing Metasite technology. Comparable to ObvioHealth as a DCT platform competitor serving large pharma sponsors with remote trial enablement.
  • Medidata Solutions: Medidata (Dassault Systèmes) is the dominant eClinical platform with Rave EDC and Patient Cloud ePRO/eConsent. Directly comparable as it offers the same core modules (eCOA, eConsent, remote data capture) that ObvioGo targets, and is the incumbent ObvioHealth explicitly positions against.
  • Veeva Systems: Veeva's Vault Clinical platform offers EDC, ePRO, and clinical operations suites widely used in pharma trials. Comparable to ObvioHealth as a Veeva EDC integration partner and as a competing clinical data management platform for enterprise sponsors.

Emerging players

  • Curebase: Curebase is an emerging DCT platform combining software with virtual site services for decentralized and hybrid trials. Comparable as a younger competitor in the same decentralized trial software + services category ObvioHealth occupies.
  • Castor (CDSS): Castor offers an eClinical platform with EDC, ePRO, and eConsent capabilities focused on flexibility and integration. Comparable as an emerging modular DCT/clinical trial platform competitor, though more research-grade than large-pharma focused.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

ObvioHealth social profiles

Digital presence

ObvioHealth compliance and trust

Trust signal

Compliance6 records

ObvioHealth financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ObvioHealth leadership team

Management profile

Number of profiles

Profiles9 records

ObvioHealth funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ObvioHealth M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ObvioHealth

What does ObvioHealth do?

ObvioHealth provides ObvioGo, an enterprise digital platform for decentralized and hybrid clinical trials that consolidates ePRO, eCOA, eConsent, participant engagement, virtual visits, and device integration into a single no-code environment. The company also operates a COACH clinical oversight team that provides in-app support and monitoring for trial participants. The platform is licensed to pharmaceutical sponsors, biotech firms, CROs, and medical device companies to design, run, and manage remote and hybrid studies.

Is ObvioHealth a public or private company?

ObvioHealth is a private company. It is classified as venture growth investor backed and is currently operating.

When was ObvioHealth founded?

ObvioHealth was founded in 2017. It employs 51 to 100 people.

Where is ObvioHealth based?

ObvioHealth is headquartered in New York, United States, in the North America region.

How does ObvioHealth make money?

Two revenue lines are on record. Platform Licensing is the primary driver. The others are enterprise Platform Subscription.

Who are ObvioHealth's main competitors?

Broad incumbents on record are ICON plc and IQVIA. Direct peers are THREAD Research, Oracle Health Sciences (Clinical One), Medable, Science 37, Medidata Solutions and Veeva Systems. Emerging players are Curebase and Castor (CDSS).

Does ObvioHealth have an API?

No public API is recorded for ObvioHealth.

What industry is ObvioHealth in?

ObvioHealth's product category is Decentralized Clinical Trial Software. Its primary akta.pro industry code is HLACAOAB, eCOA/ePRO/eDiary & Patient-Facing Data Collection. Its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireObvioHealth and SPRIM PRO Launch Integrated Digital Patient Monitoring and Clinical Support Solution for High-Risk TherapiesObvioHealth and SPRIM PRO launched an integrated digital patient monitoring and clinical support solution for high-risk therapies, combining ObvioGo's digital platform with SPRIM PRO's clinical expertise. The offering supports REMS programs, specialty therapeutics, and advanced biologics, aiming to reduce burden on patients and providers. It is designed for sponsors from late-stage development through commercialization.EIN PresswireThe Top Clinical Trial Management Software According to the FeaturedCustomers Summer 2026 Customer Success ReportFeaturedCustomers released its Summer 2026 Clinical Trial Management Software Customer Success Report, ranking vendors by customer reference content. Market Leaders include Advarra, ArisGlobal, IQVIA, Medidata, and Veeva; Top Performers include Castor EDC, CRIO, and others; Rising Stars include CliniOps, Crucial Data Solutions, and Ennov. The report is based on over 2,000 verified customer references.openPR.comVirtual Clinical Trials Market Insights on Interventional and Observational Studies Leveraging Advanced eClinical TechnologiesInsightAce Analytic Pvt. Ltd. released a market assessment report estimating the Global Virtual Clinical Trials Market will reach USD 26.3 billion by 2031, growing at a CAGR of 7.6%, driven by digital health advancements and rising chronic disease prevalence. The market faces challenges including data privacy concerns, cybersecurity risks, complex regulatory compliance, and unequal digital infrastructure access, with North America expected to maintain market leadership while Asia-Pacific shows significant growth potential. Notable recent developments include Signant Health's acquisition of DSG in July 2023 and Oracle's strategic collaboration with ObvioHealth in the Asia-Pacific region in October 2022.DealStreetAsiaSG-based ObvioHealth secures funding from new and existing investorsSingapore-based ObvioHealth has secured funding from a combination of new and existing investors. The article does not provide specific details regarding the amount raised or the identities of the participating investment firms. This financial backing supports the company's ongoing operations within the healthcare sector.PR NewswireObvioHealth and Vaxxas Sign Multi-Year Agreement to Power Needle-Free Vaccination Technology Trials with ObvioGo®ObvioHealth and Vaxxas announced a three-year partnership to support Vaxxas' late-stage clinical trials with the ObvioGo® platform. This collaboration aims to advance Vaxxas' HD-MAP needle-free vaccine delivery technology, which offers potential benefits such as reduced cold-chain storage and increased access to vaccines.Clinical Trials ArenaSPRIM PRO and ObvioHealth to provide fully integrated trial solutionSPRIM PRO and ObvioHealth, both part of the SPRIM Group, have expanded their partnership to provide a fully integrated clinical trial solution for sponsors. The collaboration combines SPRIM PRO's scientific expertise with ObvioHealth's digital platform, ObvioGo, to accelerate trial startup and enhance subject engagement through advanced endpoints. This alliance aims to deliver seamless, regulatory-ready data by integrating trial design and technology from the initial planning stages.AInvestDigital Synergy in Clinical Trials: SPRIM PRO and ObvioHealth's Paradigm ShiftSPRIM PRO and ObvioHealth partnered to accelerate clinical trials by 50% and cut participant dropout by 30% using AI-driven digital tools. Their ObvioGo platform has enrolled over 50,000 participants across 40 countries since 2023, with 20-30% cost savings. The collaboration spans 15 therapeutic areas and aims to set a new standard for decentralized trials.PR NewswireSPRIM PRO and ObvioHealth Expand Collaboration to Deliver Digitally Enabled Trials with Scientific Rigor and Global ReachSPRIM PRO and ObvioHealth, sister companies within the SPRIM Group, have expanded their collaboration to offer a fully integrated clinical trial solution combining scientific expertise with digital capabilities. The partnership pairs SPRIM PRO's 24 years of clinical experience across 300+ trials with ObvioHealth's ObvioGo platform for decentralized and hybrid trials. The unified offering is designed to help trial sponsors accelerate study startup, improve participant engagement, and deliver regulatory-ready data.PR NewswireObvioHealth Introduces ObvioGo 2.2: Transforming Study Management with AI-Driven InnovationObvioHealth released ObvioGo 2.2, adding AI-driven workflow and task management tools for clinical trials. The platform now includes real-time compliance tracking, reporting, and a centralized data repository, enabling integration with existing AI models and agentic functionalities. The release aims to improve trial efficiency and safety.ObviohealthThe First-Ever Fully Virtual Clinical Trial in UrogynecologyObvioHealth and Renovia conducted the first fully virtual clinical trial in urogynecology to assess an at-home medical device for treating urinary incontinence. The trial successfully enrolled 350 patients in 14 weeks, achieving a retention rate of 89% and lower recruitment costs of $67 per patient. This innovative approach was necessitated by the pandemic, enabling the participation of older female patients who were hesitant to attend in-person visits.